[177Lu]LuFAPI-46

N/A

Report date: 2025/11/10 17:58:28

Base Information

Drug Name[177Lu]LuFAPI-46

Drug Alias Name[177Lu]FAPI-46

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionFibroblast activation protein alpha inhibitorsPositron-emission tomography enhancers

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOsaka University

China Registration ClassN/A

Develop Information

Active CompaniesOsaka University

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A